Discovery of potent and selective inhibitors of human NLRP3 with a novel mechanism of action
Kevin Wilhelmsen(PDL BioPharma (United States)), Rebecca C. Coll(Queen's University Belfast)
Cited by 11
Related Papers
MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition
|Nature Chemical Biology|2019|975
The Cytokine Release Inhibitory Drug CRID3 Targets ASC Oligomerisation in the NLRP3 and AIM2 Inflammasomes
|PLoS ONE|2011|136
NLRP12 interacts with NLRP3 to block the activation of the human NLRP3 inflammasome
|Science Signaling|2024|40
Correction: The Cytokine Release Inhibitory Drug CRID3 Targets ASC Oligomerisation in the NLRP3 and AIM2 Inflammasomes
|PLoS ONE|2013|0
Discovery of a Potent and Selective Inhibitor of Human NLRP3 with a Novel Binding Modality and Mechanism of Action
|bioRxiv (Cold Spring Harbor Laboratory)|2024|0